Middle East And Africa Fibrotic Diseases Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 106.04 Million |
 Market Size (Forecast Year) |
USD 155.99 Million |
 CAGR |
% |
| Major Markets Players |
>中东和非洲纤维化疾病治疗市场，按治疗（药物、器官移植、氧疗等）、应用（特发性肺纤维化、肝硬化、肾纤维化、皮肤纤维化等）、最终用户（医院、专科诊所、学术和研究机构等）、分销渠道（医院药房、零售药房等）划分 - 行业趋势和预测到 2030 年。
中东和非洲纤维化疾病治疗市场分析与洞察
中东和非洲纤维化疾病治疗市场受到纤维化疾病患病率上升、吸烟人数增加以及纤维化疾病治疗技术进步等因素的推动，从而推动了市场增长。目前，发达国家和新兴国家的医疗保健支出都有所增加，这有望为制造商开发新的创新产品创造竞争优势。
中东和非洲纤维化疾病治疗市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。预测期内，推动市场需求的主要驱动力是各个地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品。
中东和非洲纤维化疾病治疗市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2022 年至 2030 年的预测期内，中东和非洲纤维化疾病治疗市场的复合年增长率将达到 4.4%。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为2015-2020） |
|
定量单位 |
收入（千美元）、定价（美元）、销量（单位） |
|
涵盖的领域 |
按治疗（药物、器官移植、氧疗、其他）、应用（特发性肺纤维化、肝硬化、肾纤维化、皮肤纤维化、其他）、最终用户（医院、专科诊所、学术和研究机构、其他）、分销渠道（医院药房、零售药房、其他） |
|
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、科威特、以色列、巴林、中东和非洲其他地区 |
|
涵盖的市场参与者 |
Boehringer Ingelheim International GmbH、AbbVie Inc.、Bristol-Myers Squibb Company、BioMX、Gilead Sciences, Inc.、Teva Pharmaceutical Industries Ltd. 和 Sandoz International GmbH 等 |
市场定义
纤维化这一术语描述了纤维结缔组织作为损伤或损伤的修复反应而形成的过程。纤维化可能指在正常愈合过程中发生的结缔组织沉积，也可能指在病理过程中发生的过量组织沉积。以不受控制的进行性纤维化为特征的疾病包括特发性肺纤维化 (IPF)、非酒精性脂肪性肝炎 (NASH) 和系统性硬化症 (SSc)。
纤维化是一组影响组织系统的严重器官/组织疾病。纤维化会使组织结疤并增厚。它会影响结缔组织，例如肺部和肺泡（肺部内的气囊）。随着时间的推移，肺部损伤逐渐加重。坚硬的肺组织无法正常扩张，使呼吸更加困难。肺纤维化可能会导致您在做以前从未感到疲劳的日常任务时呼吸困难。
中东和非洲纤维化疾病治疗市场动态
驱动程序
- 纤维化疾病患病率上升
由于衰老、肥胖、高血压或纤维化疾病家族史等各种风险因素，中东和非洲地区纤维化疾病患者数量不断增加，已成为重大的社会经济问题。因此，纤维化疾病患者数量的增加增加了治疗需求，从而推动了纤维化疾病治疗市场的发展。
- 吸烟人数增加
吸烟是导致特发性肺纤维化 (IPF) 的最重要风险因素之一。此外，最近的研究表明，吸烟可能对 IPF 患者的生存产生不利影响。吸烟导致 IPF 发病的机制在很大程度上尚不清楚。然而，越来越多的证据表明，氧化应激增加可能会促进目前或以前吸烟的 IPF 患者的疾病进展。
因此，香烟烟雾中含有颗粒物以及多种化学物质，包括剧毒的RONS，会增加体内肿胀，从而导致各种疾病，包括肺纤维化、癌症等，预计这将推动纤维化疾病治疗市场的增长。
- 纤维化疾病治疗技术进步
IPF 的特征是肺部瘢痕组织逐渐积累，患者的平均预期寿命为 2-4 年。直到最近，治疗方案仍然有限，主要集中在无效的抗炎治疗、姑息治疗、移植或试验招募。该领域近期取得的重大进展促成了两种新型抗纤维化药物吡非尼酮和尼达尼布的问世，这两种药物已被证明可以显著减缓 IPF 的病情进展。
因此，预计纤维化疾病检测和治疗技术的不断进步将推动纤维化疾病治疗市场的增长。
机会
- 研发活动不断增加
研发活动为多种疾病的治疗开辟了多种途径。新兴的技术进步以及适当的研究促成了多种治疗疾病的药物的形成。大多数人将公司的研发功能与新产品的发明联系在一起。虽然发明很重要，但现有产品的开发也同样重要，因为消费者的偏好在不断变化。
因此，预计纤维化疾病药物和治疗研发活动的增多将为纤维化疾病治疗市场的增长带来机遇。
- 开发新的、更有效的纤维化疾病治疗方法
纤维化疾病的治疗选择非常少，包括药物治疗（包括吡非尼酮和尼达尼布）、氧疗、器官移植和肺康复。
因此，针对纤维化疾病的新的、更有效的治疗方法的不断发展将为纤维化疾病治疗市场提供新的机遇。
限制/挑战
- 药物和治疗费用高昂
由于患有纤维化的患者数量不断增加，以及医疗设备和药物价格上涨，纤维化疾病的治疗费用也变得越来越昂贵。用于纤维化治疗的现代技术设备也在治疗费用高昂和准确性高方面发挥着重要作用，为特发性肺纤维化 (IPF) 提供明确的诊断。因此，纤维化疾病药物和治疗程序的高成本阻碍了市场的增长。
因此，预计与纤维化疾病的药物和治疗相关的高成本将限制纤维化疾病治疗市场的增长。
- 缺乏有效的生物标志物和诊断工具来早期发现和监测纤维化疾病
生物标志物可以测量生理和病理过程或药物作用。例如，它们可以将疾病与健康或其他类似疾病区分开来（诊断）；它们可以预测死亡率、恶化和疾病进展（预后）；以及预测对治疗的反应（治疗诊断）。
因此，发展中国家胸部成像的有限可用性被认为是诊断的主要障碍，因为胸部高分辨率计算机断层扫描是特发性肺纤维化 (IPF) 的关键诊断测试。此外，在这些国家的农村地区，获得可靠的肺功能测试和提供治疗机会很困难，这预计将抑制纤维化疾病治疗市场的增长。
- 纤维化疾病的复杂性和多因素性。
尽管复杂纤维化疾病通常聚集在家族中，但它们并没有明确的遗传模式。可能很难确定遗传因素在这些疾病中的作用，特别是因为家庭通常也共享环境，并且可能有相似的生活方式。这使得很难确定一个人遗传或传递这些疾病的风险。复杂疾病也很难研究和治疗，因为导致大多数这些疾病的具体因素尚未确定。
因此，纤维化疾病的复杂性和多因素性预计会给纤维化疾病治疗市场带来挑战。
近期发展
- 2022 年 5 月，领先的研发驱动型生物制药公司勃林格殷格翰与全球药物安全解决方案中东和非洲市场领导者 ArisMiddle East and Africa 宣布 ArisMiddle East and Africa 收购勃林格殷格翰的数字创新 BRASS。该数据洞察引擎将以 LifeSphere Clarity 的名义整合到 ArisMiddle East and Africa 的技术平台 LifeSphere 中，并将在推动全行业药物警戒和患者安全进步方面发挥关键作用。这帮助该公司将其临床诊断业务扩展到全球各个地区，并有助于提高中东和非洲在市场上的份额
- 2022 年 3 月，百时美施贵宝和 Turning Point Therapeutics, Inc. 宣布了一项最终合并协议，根据该协议，百时美施贵宝以每股 76.00 美元的价格收购 Turning Point Therapeutics。该交易得到了百时美施贵宝和 Turning Point Therapeutics 董事会的一致批准，预计将于 2022 年第三季度完成。此次收购帮助该公司扩大了其在中东和非洲市场的影响力。
中东和非洲纤维化疾病治疗市场细分
中东和非洲纤维化疾病治疗市场根据治疗、应用、最终用户和分销渠道分为四个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
治疗
- 药物
- 器官移植
- 氧气治疗
- 其他的
根据治疗方法，纤维化疾病治疗市场分为药物治疗、器官移植、氧疗和其他。
应用
- 特发性肺纤维化
- 肝硬化
- 肾纤维化
- 皮肤纤维化
- 其他的
根据应用，纤维化疾病治疗市场分为特发性肺纤维化、肝硬化、肾纤维化、皮肤纤维化等。
最终用户
- 政府组织
- 医院
- 学术和研究机构
- 其他的
根据最终用户，纤维化疾病治疗市场分为医院、专科诊所、学术和研究机构等。
分销渠道
- 医院药房
- 零售药店
- 其他的
根据分销渠道，纤维化疾病治疗市场分为医院药房、零售药房和其他。
中东和非洲纤维化疾病治疗市场区域分析/见解
对中东和非洲纤维化疾病治疗市场进行了分析，并按治疗、应用、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。
中东和非洲纤维化疾病治疗市场报告涉及的国家包括南非、沙特阿拉伯、阿联酋、埃及、科威特、以色列、巴林以及中东和非洲的其他国家。
由于发展中地区技术进步的不断加快，南非有望主导中东和非洲纤维化疾病治疗市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和纤维化疾病治疗市场份额分析
中东和非洲纤维化疾病治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对中东和非洲纤维化疾病治疗市场的关注有关。
中东和非洲纤维化疾病治疗市场的一些参与者包括勃林格殷格翰国际有限公司、艾伯维公司、百时美施贵宝公司、BioMX、吉利德科学公司、梯瓦制药工业有限公司和山德士国际有限公司等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 30 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 32 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 33 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 34 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 37 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 39 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 40 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 41 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 46 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 47 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 50 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 51 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 53 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 54 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 55 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 58 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 60 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 61 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 62 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 64 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 65 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 67 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 68 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 69 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 70 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 72 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 73 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 74 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 75 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 MARKET OVERVIEW
FIGURE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 17 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 19 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 23 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 25 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 29 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
